Zandelisib

Zandelisib

Legal status
Legal status	Investigational
Identifiers
IUPAC name 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine
CAS Number	1401436-95-0
PubChem CID	66571003
DrugBank	DB18245
ChemSpider	57617733
UNII	8Z28M5SX0X
KEGG	D12009
ChEMBL	ChEMBL4650214
Chemical and physical data
Formula	C31H38F2N8O
Molar mass	576.697 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(CC1=CC=CC=C1C2CCN(CC2)C)NC3=NC(=NC(=N3)N4CCOCC4)N5C6=CC=CC=C6N=C5C(F)F
InChI InChI=1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38) Key:WPFUFWIHMYZXSF-UHFFFAOYSA-N

Zandelisib is an investigational new drug that is being evaluated to treat follicular lymphoma. It is a phosphatidylinositol 3 kinase delta inhibitor.